http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Alessandra Vultaggio,Francesca Nencini,Susanna Bormioli,Emanuele Vivarelli,Laura Dies,Oliviero Rossi,Paola Parronchi,Enrico Maggi,Andrea Matucci 대한천식알레르기학회 2020 Allergy, Asthma & Immunology Research Vol.12 No.5
Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by multisystemic manifestations including asthma. Mepolizumab (300 mg/4 weeks) has recently been approved for EGPA. However, real-life data are scarce and report experiences with high doses of mepolizumab intravenously administered (750 mg/4 weeks). The aim of our study was to investigate in a real-life setting whether mepolizumab in EGPA patients at low doses would enable us 1) to control asthma symptoms, 2) to obtain oral corticosteroids (OCS) and/or immunosuppressors tapering and 3) to maintain clinical remission and avoid disease relapses. Mepolizumab (100 mg/4 weeks) was subcutaneously administered for 12 months in 18 EGPA patients with uncontrolled severe asthma. Symptoms, annual asthma exacerbation rates, OCS-sparing effects, lung function and eosinophil activation markers were monitored. The proportion of patients with clinical remission or relapse was also evaluated in month 12. A significant decrease in the annual rate of asthma exacerbations in association with significant changes in asthma control were observed. Specifically, 66.6% of the patients experienced no exacerbations during the mepolizumab treatment. Most patients (77.7%) were able to reduce the daily OCS dose by at least 50%. Four patients also stopped cyclosporine A during the study period. No EGPA relapse was observed and a large majority of the patients achieved clinical remission (94.3%). Clinical benefits were paralleled by reduction in blood eosinophils and serum levels of eosinophil activation markers. Low-dose mepolizumab showed clinically relevant benefits in exacerbation rates, asthma symptoms, OCS and immunosuppressive use in EGPA patients. These effects occurred without any EGPA relapse for extrapulmonary manifestations.
Tests of a dual-readout fiber calorimeter with SiPM light sensors
Antonello, M.,Caccia, M.,Cascella, M.,Dunser, M.,Ferrari, R.,Franchino, S.,Gaudio, G.,Hall, K.,Hauptman, J.,Jo, H.,Kang, K.,Kim, B.,Lee, S.,Lerner, G.,Pezzotti, L.,Santoro, R.,Vivarelli, I.,Ye, R.,Wig Elsevier 2018 Nuclear Instruments & Methods in Physics Research. Vol.899 No.-
<P><B>Abstract</B></P> <P>In this paper, we describe the first tests of a dual-readout fiber calorimeter in which silicon photomultipliers are used to sense the (scintillation and Čerenkov) light signals. The main challenge in this detector is implementing a design that minimizes the optical crosstalk between the two types of fibers, which are located very close to each other and carry light signals that differ in intensity by about a factor of 60. The experimental data, which were obtained with beams of high-energy electrons and muons as well as in lab tests, illustrate to what extent this challenge was met. The Čerenkov light yield, a limiting factor for the energy resolution of this type of calorimeter, was measured to be about twice that of the previously tested configurations based on photomultiplier tubes. The lateral profiles of electromagnetic showers were measured on a scale of millimeters from the shower axis and significant differences were found between the profiles measured with the scintillating and the Čerenkov fibers.</P>